Citations

Clear

6273 citation(s) found for "To, Andrew".

B7-H4–deficient mice display augmented neutrophil-mediated innate immunity
Zhu, Gefeng, Augustine, Mathew M., Azuma, Takeshi , Luo, Liqun , Yao, Sheng , Anand, Sudarshan , Rietz, A., Huang, Jiaqiang , Xu, Haiying, Flies, Andrew S. , Flies, Sarah J., Tamada, Koji , Colonna, Marco , Deursen, Jan M. A. van, Chen, Lieping , Colonna, Marco

Mayo Clinic

Blood | December 24, 2008 | Volume: 113 | Issue: 8 | Pages: 1759-1767

10.1182/blood-2008-01-133223 | PMID 19109567 Get It

Abstract B7-H4 is an immunoglobulin superfamily molecule and shown to be inhibitory for T-cell responses. To explore physiologic roles of B7-H4, we created B7-H4–deficient (KO) mice by genetic targeting. B7-H4KO mice are healthy and their T- and B-cell responses to polyclonal antigens are in normal range. However, B7-H4KO mice are more resistant to infection by Listeria monocytogenes than their littermates. Within 3 days after infection, bacterial colonies in livers and spleens are significantly lower than the controls, suggesting a role of B7-H4 in enhancing innate immunity. Further studies demonstrate that neutrophils increase in peripheral organs of B7-H4KO mice more so than their littermates but their bactericidal functions remain unchanged. Augmented innate resistance is completely dependent on neutrophils, even in the absence of adaptive immunity. In vitro B7-H4 inhibits the growth of bone marrow–derived neutrophil progenitors, suggesting an inhibitory function of B7-H4 in neutrophil expansion. Our results identify B7-H4 as a negative regulator of the neutrophil response to infection and provide a new target for manipulation of innate immunity.
Treatment of Congenital Endplate Acetylcholinesterase Deficiency by Neuromuscular Blockade
Breningstall, Galen N. , Kurachek, Stephen C. , Fugate, John H., Engel, Andrew G.

Mayo Clinic

Journal of Child Neurology | December 24, 2008 | Volume: 11 | Issue: 4 | Pages: 345-346

10.1177/088307389601100416 | PMID 8807428 Get It

Percutaneous Nephrolithotomy Success in the Transplant Kidney
Krambeck, Amy E. , LeRoy, Andrew J., Patterson, David E., Gettman, Matthew T.

Mayo Clinic

Journal of Urology | December 17, 2008 | Volume: 180 | Issue: 6 | Pages: 2545-2549

10.1016/j.juro.2008.08.032 | PMID 18930500 Get It

Polymorphism in theIL18Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women
Palmieri, Rachel T., Wilson, Melanie A., Iversen, Edwin S., Clyde, Merlise A. , Calingaert, Brian , Moorman, Patricia G. , Poole, Charles, Anderson, S. Keith , Beesley, Jonathan, Høgdall, Estrid , Carney, Michael E., Chen, Xiaoqing , Chenevix‐Trench, Georgia , Chang‐Claude, Jenny , Cunningham, Julie M. , DiCioccio, Richard A., Easton, Douglas F. , Edlund, Christopher K., Gayther, Simon A. , Goode, Ellen L. , Goodman, Marc T. , Kjær, Susanne K. , Høgdall, Claus , Hopkins, Michael P., Jenison, Eric L., Blaakær, Jan , Lurie, Galina, McGuire, Valerie, Menon, Usha , Moysich, Kirsten B. , Ness, Roberta B., Pearce, Celeste Leigh , Pike, Malcolm C. , Ramus, Susan J. , Rossing, Mary Anne, Song, Honglin , Terada, Keith Y. , VanDenBerg, David, Vierkant, Robert A. , Wang‐Gohrke, Shan , Webb, Penelope M. , Whittemore, Alice S. , Wu, Anna H. , Schildkraut, Joellen M. , Bowtell, David D.L. , Weber, Rachel Palmieri , Anderson, Alisha R. , Anton‐Culver, Hoda , Brewster, Wendy R. , Doherty, Jennifer A. , Gentry‐Maharaj, Aleksandra , Pharoah, Paul D.P. , Ziogas, Argyrios , Berchuck, Andrew , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Bowtell, David D , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | December 8, 2008 | Volume: 17 | Issue: 12 | Pages: 3567-3572

10.1158/1055-9965.epi-08-0548 | PMID 19064572 Get It

AbstractOver 22,000 cases of ovarian cancer were diagnosed in 2007 in the United States, but only a fraction of them can be attributed to mutations in highly penetrant genes such as BRCA1. To determine whether low-penetrance genetic variants contribute to ovarian cancer risk, we genotyped 1,536 single nucleotide polymorphisms (SNP) in several candidate gene pathways in 848 epithelial ovarian cancer cases and 798 controls in the North Carolina Ovarian Cancer Study (NCO) using a customized Illumina array. The inflammation gene interleukin-18 (IL18) showed the strongest evidence for association with epithelial ovarian cancer in a gene-by-gene analysis (P = 0.002) with a <25% chance of being a false-positive finding (q value = 0.240). Using a multivariate model search algorithm over 11 IL18 tagging SNPs, we found that the association was best modeled by rs1834481. Further, this SNP uniquely tagged a significantly associated IL18 haplotype and there was an increased risk of epithelial ovarian cancer per rs1834481 allele (odds ratio, 1.24; 95% confidence interval, 1.06-1.45). In a replication stage, 12 independent studies from the Ovarian Cancer Association Consortium (OCAC) genotyped rs1834481 in an additional 5,877 cases and 7,791 controls. The fixed effects estimate per rs1834481 allele was null (odds ratio, 0.99; 95% confidence interval, 0.94-1.05) when data from the 12 OCAC studies were combined. The effect estimate remained unchanged with the addition of the initial North Carolina Ovarian Cancer Study data. This analysis shows the importance of consortia, like the OCAC, in either confirming or refuting the validity of putative findings in studies with smaller sample sizes. (Cancer Epidemiol Biomarkers Prev 2008;17(12):3567–72)
Inhibition of Repair of Radiation-Induced DNA Damage Enhances Gene Expression from Replication-Defective Adenoviral Vectors
Hingorani, Mohan , Merron, Andrew, Peerlinck, Inge, Gore, Martin, Slade, Andrew, Scott, Simon D. , Nutting, Christopher M. , Pandha, Hardev , Melcher, Alan , Vile, Richard G. , Vassaux, Georges , Harrington, Kevin J. , White, Christine L. , Melcher, Alan A , Harrington, Kevin

Mayo Clinic

Cancer Research | December 1, 2008 | Volume: 68 | Issue: 23 | Pages: 9771-9778

10.1158/0008-5472.can-08-1911 | PMID 19047156 Get It

Abstract Radiation has been shown to up-regulate gene expression from adenoviral vectors in previous studies. In the current study, we show that radiation-induced dsDNA breaks and subsequent signaling through the mitogen-activated protein kinase (MAPK) pathway are responsible, at least in part, for this enhancement of transgene expression both in vitro and in vivo. Inhibitors of ataxia-telangiectasia–mutated, poly(ADP-ribose) polymerase–mutated, and DNA-dependent protein kinase (DNA-PK)–mediated DNA repair were shown to maintain dsDNA breaks (γH2AX foci) by fluorescence-activated cell sorting and microscopy. Inhibition of DNA repair was associated with increased green fluorescent protein (GFP) expression from a replication-defective adenoviral vector (Ad-CMV-GFP). Radiation-induced up-regulation of gene expression was abrogated by inhibitors of MAPK (PD980059 and U0126) and phosphatidylinositol 3-kinase (LY294002) but not by p38 MAPK inhibition. A reporter plasmid assay in which GFP was under the transcriptional control of artificial Egr-1 or cytomegalovirus promoters showed that the DNA repair inhibitors increased GFP expression only in the context of the Egr-1 promoter. In vivo administration of a water-soluble DNA-PK inhibitor (KU0060648) was shown to maintain luciferase expression in HCT116 xenografts after intratumoral delivery of Ad-RSV-Luc. These data have important implications for therapeutic strategies involving multimodality use of radiation, targeted drugs, and adenoviral gene delivery and provide a framework for evaluating potential advantageous combinatorial effects. [Cancer Res 2008;68(23):9771–8]
Current Issues in Measurement and Reporting of Urinary Albumin Excretion
Miller, W. Greg , Bruns, David E., Hortin, Glen L. , Sandberg, Sverre , Aakre, Kristin M. , McQueen, Matthew, Itoh, Yoshihisa, Seccombe, David , Jones, Graham , Bunk, David M. , Narva, Andrew S., Urine, on behalf of the National Kidney Disease Education Program-IFCC Working Group on Standardization of Albumin in, Lieske, John C. , Curhan, Gary C. , Urine, on behalf of the National Kidney Disease Education Program-IFCC Working Group on Standardization of Albumin in, Aakre, Kristin M

Mayo Clinic

Clinical Chemistry | November 21, 2008 | Volume: 55 | Issue: 1 | Pages: 24-38

10.1373/clinchem.2008.106567 | PMID 19028824 Get It

Abstract Background: Urinary excretion of albumin indicates kidney damage and is recognized as a risk factor for progression of kidney disease and cardiovascular disease. The role of urinary albumin measurements has focused attention on the clinical need for accurate and clearly reported results. The National Kidney Disease Education Program and the IFCC convened a conference to assess the current state of preanalytical, analytical, and postanalytical issues affecting urine albumin measurements and to identify areas needing improvement. Content: The chemistry of albumin in urine is incompletely understood. Current guidelines recommend the use of the albumin/creatinine ratio (ACR) as a surrogate for the error-prone collection of timed urine samples. Although ACR results are affected by patient preparation and time of day of sample collection, neither is standardized. Considerable intermethod differences have been reported for both albumin and creatinine measurement, but trueness is unknown because there are no reference measurement procedures for albumin and no reference materials for either analyte in urine. The recommended reference intervals for the ACR do not take into account the large intergroup differences in creatinine excretion (e.g., related to differences in age, sex, and ethnicity) nor the continuous increase in risk related to albumin excretion. Discussion: Clinical needs have been identified for standardization of (a) urine collection methods, (b) urine albumin and creatinine measurements based on a complete reference system, (c) reporting of test results, and (d) reference intervals for the ACR.
Relationship Between Parenting Stress and Concerns Identified by Developmental Screening and Their Effects on Parental Medical Care—Seeking Behavior
Voigt, Robert G. , Johnson, Shirley K., Mellon, Michael W., Hashikawa, Andrew N. , Campeau, Lynnelle J., Williams, Arthur R., Yawn, Barbara P. , Juhn, Young J.

Mayo Clinic

Clinical Pediatrics | November 20, 2008 | Volume: 48 | Issue: 4 | Pages: 362-368

10.1177/0009922808327058 | PMID 19023111 Get It

This cross-sectional study examines the relationship between parenting stress and concerns identified by developmental screening and their effects on parents' decisions to seek medical care for their children. A total of 182 parents completed both the Parenting Stress Index (PSI) and the Parents' Evaluation of Developmental Status (PEDS) when their children were admitted to a sick child care program that provides parents the option of requesting medical evaluations for their children with mild acute illnesses. Although 31.6% of parents (N = 62) requested medical evaluations, neither PSI nor PEDS scores were associated with these requests. However, PEDS scores indicating significant parental concerns about their child's development or behavior predicted clinically significant levels of parenting stress on the PSI (odds ratio 4.9; 95% confidence interval, 1.5-15.9; P = .007). Primary pediatric health care providers who routinely perform developmental screening need to consider this relationship when interpreting developmental screening results and offer supportive and referral services to families as needed.
International Lung Cancer Consortium: Pooled Analysis of Sequence Variants in DNA Repair and Cell Cycle Pathways
Hung, Rayjean J., Risch, Angela , Popanda, Odilia , Haugen, Aage, Zienolddiny, Shanbeh , Benhamou, Simone , Bouchardy, Christine , Lan, Qing , Spitz, Margaret R., Wichmann, H. E., Vineis, Paolo , Matullo, Giuseppe , Kiyohara, Chikako , Zhang, Zuo‐Feng , Pezeshki, Benhnaz, Harris, Curtis C. , Mechanic, Leah E. , Seow, Adeline , Ng, Daniel , Szeszenia‐Dąbrowska, Neonila, Заридзе, Давид , Lissowska, Jolanta , Rudnai, Péter, Fabiánová, Eleonóra , Mateș, Dana , Foretová, Lenka , Janout, Vladimí­r , Bencko, Vladimír , Caporaso, Neil E. , Chen, Chu , Duell, Eric J. , Goodman, Gary E. , Field, John K. , Houlston, Richard S. , Landi, Maria Teresa , McLaughlin, John, Schwartz, Ann G. , Stücker, Isabelle, Tajima, Kazuo, Matsuo, Keitaro , Thun, Michael J., Andrew, Angeline S. , Monnier, Stéphanie, Brennan, Paul , Hung, Rayjean J. , Hung, Rayjean J., Christiani, David C. , Marchand, Loı̈c Le , Hong, Yun‐Chul , Lazarus, Philip J. , Muscat, Joshua E. , McLaughlin, John, Shen, Hongbing , Yang, Ping , Wiencke, John K. , Boffetta, Paolo , Houlston, Richard S , Lissowska, Jolanta , Duell, Eric J , Hung, Rayjean J , Field, John K , Matsuo, Keitaro , Mates, Dana , Matullo, Giuseppe , Risch, Angela , Zienolddiny, Shanbeh

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | November 6, 2008 | Volume: 17 | Issue: 11 | Pages: 3081-3089

10.1158/1055-9965.epi-08-0411 | PMID 18990748 Get It

Abstract Background: The International Lung Cancer Consortium was established in 2004. To clarify the role of DNA repair genes in lung cancer susceptibility, we conducted a pooled analysis of genetic variants in DNA repair pathways, whose associations have been investigated by at least 3 individual studies. Methods: Data from 14 studies were pooled for 18 sequence variants in 12 DNA repair genes, including APEX1, OGG1, XRCC1, XRCC2, XRCC3, ERCC1, XPD, XPF, XPG, XPA, MGMT, and TP53. The total number of subjects included in the analysis for each variant ranged from 2,073 to 13,955 subjects. Results: Four of the variants were found to be weakly associated with lung cancer risk with borderline significance: these were XRCC3 T241M [heterozygote odds ratio (OR), 0.89; 95% confidence interval (95% CI), 0.79-0.99 and homozygote OR, 0.84; 95% CI, 0.71-1.00] based on 3,467 cases and 5,021 controls from 8 studies, XPD K751Q (heterozygote OR, 0.99; 95% CI, 0.89-1.10 and homozygote OR, 1.19; 95% CI, 1.02-1.39) based on 6,463 cases and 6,603 controls from 9 studies, and TP53 R72P (heterozygote OR, 1.14; 95% CI, 1.00-1.29 and homozygote OR, 1.20; 95% CI, 1.02-1.42) based on 3,610 cases and 5,293 controls from 6 studies. OGG1 S326C homozygote was suggested to be associated with lung cancer risk in Caucasians (homozygote OR, 1.34; 95% CI, 1.01-1.79) based on 2,569 cases and 4,178 controls from 4 studies but not in Asians. The other 14 variants did not exhibit main effects on lung cancer risk. Discussion: In addition to data pooling, future priorities of International Lung Cancer Consortium include coordinated genotyping and multistage validation for ongoing genome-wide association studies. (Cancer Epidemiol Biomarkers Prev 2008;17(11):3081–9)
A functional folate receptor is induced during macrophage activation and can be used to target drugs to activated macrophages
Xia, Wei , Hilgenbrink, Andrew R., Matteson, Eric L. , Lockwood, Michael B, Low, Philip S. , Cheng, Ji‐Xin

Mayo Clinic

Blood | October 24, 2008 | Volume: 113 | Issue: 2 | Pages: 438-446

10.1182/blood-2008-04-150789 | PMID 18952896 Get It

Abstract Previous work has demonstrated that a subset of macrophages expresses a folate receptor (FR) that can mediate internalization of folate-linked molecules, including imaging and therapeutic agents. To characterize this subset, macrophages were collected from peritoneal cavities of mice injected with saline, thioglycolate, zymosan, heat-killed or live bacteria, and cell-surface markers that coexpress with FR were identified. Virtually no F4/80+ peritoneal macrophages from saline-injected mice expressed FR, whereas numerous macrophages from mice injected with each inflammatory stimulus expressed FR. Examination of cell differentiation antigens that are up-regulated in FR+ macrophages revealed markers characteristic of an activated state (CD80, CD86, Ly-6C/G), whereas macrophages lacking these activation markers expressed few or no FR. FR+ macrophages also produced tumor necrosis factor-α (TNF-α) and reactive oxygen species, and production of reactive oxygen species correlated linearly with expression of FR. Synovial macrophages collected from arthritic patients were found to bind and internalize folate-linked dyes. Moreover, a folate-linked radioimaging agent was shown to image inflamed joints of rheumatoid arthritic patients. These results suggest that FR constitutes a marker for macrophage activation and that FR+ macrophages can be targeted with folate-linked drugs without promoting drug uptake by nonactivated macrophages. This trial was registered at www.clinicaltrials.gov as #NCT00588393.
Embolic Potential of Cardiac Tumors and Outcome After Resection
ElBardissi, Andrew W., Daly, Richard C. , Mullany, Charles J., Orszulak, Thomas A., Puga, Francisco J., Schaff, Hartzell V. , Dearani, Joseph A. , Schaff, Hartzell

Mayo Clinic

Stroke | October 24, 2008 | Volume: 40 | Issue: 1 | Pages: 156-162

10.1161/strokeaha.108.525709 | PMID 18948602 Get It

Background and Purpose— Embolic events have long been thought to occur in patients with cardiac tumors secondary to embolization of tumor fragments; however, there are no large studies examining the epidemiology and occurrence of embolism in this group of patients. Methods— From 1957 to 2006, 323 consecutive patients with primary cardiac tumors were treated surgically at our institution. Of these, patients who experienced an embolic event included 80 (cerebrovascular accident 31 [9.7%], transient ischemic attack 30 [9.3%], and other 19 [6%]). Those with no history of an embolic event (n=243 [75%]) were defined as control subjects. Results— Age was similar between the case and control groups (mean 54.5 versus 53.9 years, P =0.8). A multivariate logistic regression model including tumor location, tumor burden, tumor histology, and cerebrovascular risk factors, indicated that left atrial tumors (OR, 1.95; P =0.04), aortic valve tumors (OR, 4.17; P =0.002), and smaller tumor burden (OR, 2.20; P =0.01) were the most significant factors in the occurrence of embolism ( P <0.001). The presence of mitral regurgitation (OR, 0.12; P =0.006) and decreased functional status (New York Heart Association III/IV; OR, 0.31; P <0.001) were protective against the occurrence of embolism. Follow-up was obtained in 82% at a mean follow-up time of 6.17±6.9 years. There were no recurrent embolic events at follow-up. A Kaplan-Meier survival curve demonstrated no difference in survival between both groups ( P =0.78). Conclusion— Aortic valve and left atrial tumors have the greatest anatomic risk for embolism. Furthermore, patients with smaller tumors, minimal symptomatology, and no evidence of mitral regurgitation have a high risk of embolism. Cardiac tumors can be resected with low early mortality, and late survival after operation in the context of an embolic event is similar to patients with cardiac tumors who undergo resection for other indications.